Compare Stocks: FBRX, KNSA, RYTM, and LGND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$76.99	$74.59	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
KNSA Kiniksa Pharmaceuticals International	$80.79 +1.4%	$78.13	$35.20 ▼ $84.06	$6.22B	0.04	617,384 shs	429,626 shs
LGND Ligand Pharmaceuticals	$307.82 -2.2%	$293.50	$175.89 ▼ $326.63	$6.28B	1.14	250,487 shs	315,128 shs
RYTM Rhythm Pharmaceuticals	$90.90 +2.6%	$99.68	$74.50 ▼ $122.20	$6.07B	2.01	765,281 shs	516,393 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	0.00%	0.00%	0.00%	+40.54%	+560.29%
KNSA Kiniksa Pharmaceuticals International	+1.37%	+1.06%	+3.58%	+28.56%	+107.69%
LGND Ligand Pharmaceuticals	-2.21%	+3.12%	+3.12%	+2.43%	+65.88%
RYTM Rhythm Pharmaceuticals	+2.57%	+3.33%	-8.43%	-10.97%	-16.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$76.99	$74.59	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
KNSA Kiniksa Pharmaceuticals International	$80.79 +1.4%	$78.13	$35.20 ▼ $84.06	$6.22B	0.04	617,384 shs	429,626 shs
LGND Ligand Pharmaceuticals	$307.82 -2.2%	$293.50	$175.89 ▼ $326.63	$6.28B	1.14	250,487 shs	315,128 shs
RYTM Rhythm Pharmaceuticals	$90.90 +2.6%	$99.68	$74.50 ▼ $122.20	$6.07B	2.01	765,281 shs	516,393 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	0.00%	0.00%	0.00%	+40.54%	+560.29%
KNSA Kiniksa Pharmaceuticals International	+1.37%	+1.06%	+3.58%	+28.56%	+107.69%
LGND Ligand Pharmaceuticals	-2.21%	+3.12%	+3.12%	+2.43%	+65.88%
RYTM Rhythm Pharmaceuticals	+2.57%	+3.33%	-8.43%	-10.97%	-16.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
KNSA Kiniksa Pharmaceuticals International	2.89	Moderate Buy	$93.14	15.29% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	9.77% Upside
RYTM Rhythm Pharmaceuticals	2.77	Moderate Buy	$142.50	56.77% Upside

Current Analyst Ratings Breakdown

Latest FBRX, KNSA, RYTM, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	RYTM Rhythm Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$146.00 ➝ $145.00
10/12/2026	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$155.00 ➝ $159.00
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$87.00
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$345.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$358.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$390.00 ➝ $397.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.30	$0.80 per share	100.41	$7.44 per share	10.86
LGND Ligand Pharmaceuticals	$268.09M	22.90	$7.68 per share	40.09	$51.68 per share	5.96
RYTM Rhythm Pharmaceuticals	$189.76M	32.83	N/A	N/A	$2.08 per share	43.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	83.29	39.03	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	32.92	36.86	2.52	67.88%	20.06%	11.68%	10/29/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest FBRX, KNSA, RYTM, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7101	N/A	N/A	N/A	$85.48 million	N/A
10/29/2026	Q3 2026	LGND Ligand Pharmaceuticals	$2.33	N/A	N/A	N/A	$77.00 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3722	N/A	N/A	N/A	$260.22 million	N/A
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	10.01	10.01
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
KNSA Kiniksa Pharmaceuticals International	53.95%
LGND Ligand Pharmaceuticals	91.28%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	4.40%
KNSA Kiniksa Pharmaceuticals International	51.98%
LGND Ligand Pharmaceuticals	5.60%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

FBRX, KNSA, RYTM, and LGND Headlines

Recent News About These Companies

William Blair initiates coverage of Rhythm Pharmaceuticals at outperform

October 22 at 6:50 PM | msn.com

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 21 at 8:00 AM | globenewswire.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with 67% Upside Potential

October 19, 2026 | directorstalkinterviews.com

176,882 Rhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Assenagon Asset Management S.A.

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Stock Sold by Aspiriant LLC

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Target Cut by JPMorgan Chase & Co.

October 17, 2026 | americanbankingnews.com

HC Wainwright Issues Optimistic Outlook for RYTM Earnings

October 16, 2026 | americanbankingnews.com

JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

October 15, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Has Lowered Expectations for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

October 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. Announces Commercial Launch of IMCIVREE® (Setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 14, 2026 | marketscreener.comM

Rhythm launches IMCIVREE in Japan

October 14, 2026 | grafa.comG

Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity

October 14, 2026 | rttnews.com

HC Wainwright Has Positive Outlook for RYTM Q3 Earnings

October 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 13, 2026 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

October 13, 2026 | zacks.com

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies

October 13, 2026 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 52.99% Upside Potential

October 12, 2026 | directorstalkinterviews.com

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

October 9, 2026 | finance.yahoo.com

RBC raises target for Rhythm Pharmaceuticals stock to USD 159

October 8, 2026 | ad-hoc-news.deA

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $140.67

September 30, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

September 28, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX, KNSA, RYTM, and LGND Company Descriptions

Forte Biosciences NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$80.79 +1.09 (+1.37%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$81.20 +0.41 (+0.50%)

As of 04:31 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Ligand Pharmaceuticals NASDAQ:LGND

$307.82 -6.96 (-2.21%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$306.96 -0.86 (-0.28%)

As of 04:00 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Rhythm Pharmaceuticals NASDAQ:RYTM

$90.90 +2.28 (+2.57%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$89.48 -1.42 (-1.57%)

As of 04:21 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBRX, KNSA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBRX, KNSA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBRX, KNSA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX, KNSA, RYTM, and LGND Company Descriptions

Forte Biosciences NASDAQ:FBRX

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Ligand Pharmaceuticals NASDAQ:LGND

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBRX, KNSA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBRX, KNSA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBRX, KNSA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX, KNSA, RYTM, and LGND Company Descriptions

Forte Biosciences NASDAQ:FBRX

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Ligand Pharmaceuticals NASDAQ:LGND

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools